Diagnosis, clinical characteristics, and outcomes of COVID-19 patients from a large healthcare system in northern New Jersey

Abstract

New Jersey was an early epicenter for the COVID-19 pandemic in the United States, yet information on hospitalized COVID-19 patients from this area is scarce. This study aimed to provide data on demographics and clinical features of a hospitalized patient population who were confirmed with infection by our in-house (CDI) real-time reverse-transcription polymerase chain reaction (RT-PCR) test. We included consecutive patients who were admitted to Hackensack Meridian Health system hospitals with laboratory-confirmed diagnoses of COVID-19 at Hackensack University Medical Center by the CDI virus test between March 12, 2020, and April 8, 2020. Clinical data and viral testing results were collected and analyzed for characteristics associated with outcomes, as well as the correlation with viral load. A total of 722 patients were included in the study, with a median age of 63 (interquartile range (IQR), 51–75) and 272 (37.7%) females. Mortality of this case series was 25.8%, with a statistically significant linear increase observed from age 40 to ≥ 80 by 10-year intervals. Viral load, as indicated by the cycle of threshold (Ct) values from the RT-PCR test, was significantly higher in the oldest patient group (≥ 80), and inversely correlated with survival. This is the first report to describe the clinical characteristics and outcomes in a large hospitalized COVID-19 patient series from New Jersey. Findings from this study are valuable to the ongoing response of both nationwide healthcare networks and the medical research community.

Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment

“…Total nucleic acid (TNA) from nasopharyngeal swabs was extracted by the MagNAPure 24 system (Roche Life Science), and viral RNA from tracheal aspirates was extracted using QIAamp viral RNA minikit (Qiagen), according to the manufacturer’s instructions. SARS-CoV-2 detection was performed using our in-house developed and enhanced COVID-19 test ( 18 ), targeting SARS-CoV-2 E and N2 genes. The test was approved for use on 12 March 2020 under FDA Emergency Use Authorization for COVID-19 and has a limit of detection of less than 20 viral genome copies per reaction.…”

Evaluating spatial accessibility to COVID-19 vaccine resources in diversely populated counties in the United States

“…This study was performed in Essex County and Union County, New Jersey. New Jersey is one of the most affected US states in the COVID-19 pandemic ( 40 ) and the impact has been disproportionately concentrated among Black and Hispanic populations ( 22 , 23 ). The two counties selected for analysis of vaccine accessibility are located within close proximity to New York City and Newark International Airport, making them a major transmission hub during each wave of the pandemic.…”

Current clinical status of new COVID-19 vaccines and immunotherapy

“…The ongoing SARS-CoV-2 pandemic caused havoc to public health infrastructure, with no approved therapy, affecting millions around the globe. The outbreak was first reported on the 31st of December 2019 to the WHO (Zhao et al 2021 ). The coronavirus was designated as “2019-nCoV” by the WHO on 12th of January 2020 and then termed SARS-CoV-2.…”